KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Expenses (2020 - 2025)

Recursion Pharmaceuticals' Operating Expenses history spans 6 years, with the latest figure at $143.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 23.6% year-over-year to $143.9 million; the TTM value through Dec 2025 reached $722.8 million, up 34.39%, while the annual FY2025 figure was $722.8 million, 34.39% up from the prior year.
  • Operating Expenses reached $143.9 million in Q4 2025 per RXRX's latest filing, down from $177.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $206.1 million in Q1 2025 to a low of $33.0 million in Q1 2021.
  • Average Operating Expenses over 5 years is $106.7 million, with a median of $101.3 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 138.73% in 2021, then decreased 23.6% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $67.5 million in 2021, then rose by 10.62% to $74.7 million in 2022, then soared by 47.1% to $109.8 million in 2023, then soared by 71.47% to $188.3 million in 2024, then fell by 23.6% to $143.9 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Operating Expenses are $143.9 million (Q4 2025), $177.4 million (Q3 2025), and $195.4 million (Q2 2025).